# DSGN catalysts: Design Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/dsgn/catalysts

> Design Therapeutics, Inc. (DSGN) has 2 upcoming catalysts. The next is the DT-168 primary completion, December 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Design Therapeutics, Inc. |
| Ticker | DSGN (Nasdaq) |
| SEC CIK | 1807120 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/dsgn |

## Cash runway

Cash $208.6M as of 2026-09-30; quarterly burn $15.4M; about 40.7 months of runway at that rate (XBRL company facts, accession 0001193125-26-447258).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [DT-216 interim data readout](https://sec-api.dev/pdufa/dt-216) | DSGN |  | completed, positive | "In December 2022, we reported positive initial data from the Phase 1 single-ascending dose (SAD) clinical trial and in August 2023, we reported data from the Phase 1 multiple-ascending dose (MAD) clinical trial of the prior DT-216 product candidate." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1807120/000119312525266970/dsgn-20250930.htm)) |
| Oct 2023 | [DT-216 trial start](https://sec-api.dev/pdufa/dt-216) | DSGN |  | completed | "We withdrew our IND for the prior DT-216 product candidate in October 2023, and have initiated a Phase 1 SAD clinical trial in normal healthy volunteers in Australia to evaluate single doses using multiple routes of administration of DT-216P2, which uses the same drug substance, DT-216." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1807120/000119312525266970/dsgn-20250930.htm)) |
| March 10, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025035909/dsgn-ex99_1.htm)) |
| May 7, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-ex99_1.htm)) |
| 2H 2025 | [DT-168 trial start](https://sec-api.dev/pdufa/dt-168) | DSGN |  | scheduled | "Design plans to initiate the Phase 2 biomarker trial in the second half of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025065613/dsgn-ex99_1.htm)) |
| August 7, 2025 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Second Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000095017025105008/dsgn-ex99_1.htm)) |
| November 5, 2025 | [DT-818 earnings report](https://sec-api.dev/pdufa/dt-818) | DSGN |  | completed | "Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312525266933/dsgn-ex99_1.htm)) |
| 1H 2026 | [DT-818 trial start](https://sec-api.dev/pdufa/dt-818) | DSGN |  | scheduled | "Myotonic Dystrophy Type-1 (DM1): Design expects to begin dosing DM1 patients in its Phase 1 multiple-ascending dose (MAD) trial of DT-818, a GeneTAC® small molecule designed to selectively reduce transcription of the mutant DMPK allele, in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-ex99_1.htm)) |
| March 9, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/dsgn-ex99_1.htm)) |
| April 28, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526187012/dsgn-ex99_1.htm)) |
| August 3, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526329570/dsgn-ex99_1.htm)) |
| November 4, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Announces Third Quarter 2026 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526447235/dsgn-ex99_1.htm)) |
| December 2027 | [DT-168 primary completion](https://sec-api.dev/pdufa/dt-168) | DSGN | Fuchs Endothelial Corneal Dystrophy; Fuchs | scheduled | "NCT07024693 (DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Design Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024693)) |
| Dec 2027 to Mar 2028 | [DT-168 topline data readout](https://sec-api.dev/pdufa/dt-168) | DSGN | Fuchs Endothelial Corneal Dystrophy; Fuchs | scheduled | "NCT07024693 (DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Design Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07024693)) |

## Drugs

- [DT-168](https://sec-api.dev/pdufa/dt-168): Fuchs Endothelial Corneal Dystrophy
- [DT-216](https://sec-api.dev/pdufa/dt-216): 
- [DT-818](https://sec-api.dev/pdufa/dt-818): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/dsgn/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "DSGN catalysts: Design Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/dsgn/catalysts

```bibtex
@misc{secapidev_companies_dsgn_catalysts_20261116,
  title        = {DSGN catalysts: Design Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/dsgn/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_dsgn_catalysts_20261116","title":"DSGN catalysts: Design Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/dsgn/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
